Breakthrough in the Treatment of ALDD

Roberta E. Illiot, M.D., chief resident of Neurosurgery at NYCCU Lasagna Medical Center, has presented results of the study entitled, "Group A Placebos Out-Perform Groups B, C and RS in Treatment of Adult Logic Deficiency Disorder." The study was designed to analyze the efficacy and safety of certain placebos in a large series of consecutive adults diagnosed with Type A Logic Deficiency Disorder (also known as "Common Sense Disorder").

Dr. Illiott and her colleagues at NYCCU Lasagna Medical Center conducted a retrospective review of 507 consecutive patients with Adult Logic Deficiency Disorder who ingested a total of 772,000 placebos between November 1997 and April 2009. Outcome analysis was performed on 436 patients from a Control Group (Group A), a test group (Group B), another test group (Group C) and a random sample (Group RS) who, thrice daily, ingested placebos composed chiefly of marzipan, M&Ms, and Reese's Peanut Butter Cups, and who had at least one year of follow-up since date of last ingestion. Duration of the Placebo Therapy ranged from one week to 11.35 years, with the patients who lasted for the entire 11.35 years either being incredibly slow to catch on, or (as Dr. Illiot speculates) having become "addicted" to one or two of the key ingredients in the placebo.

The results showed that a more than 50 percent reduction in logic deficiency occurred in 64.6 percent of patients, and 42.1 percent of patients experienced more than a 70 percent reduction in logic deficiency. 79 percent of patients who experienced more than a 70 percent reduction were 87 percent less likely to exhibit characteristics simpatico with 23 per cent of patients who had demonstrated a 73 per cent likelihood of recidivism (i.e., extra-curricular placebo ingestion) in 98 percent of documented cases. Patients who had exhibited a near total blockage of common sense had similar outcomes to those who did not have prior therapy. In a statistically significant number of patients (all), patients who demonstrated a reduction in logic deficiency through rigorous adherence to the placebo dosage exhibited a concomitant weight gain.

Across the board, patients in Group A had strikingly better results than patients in all other groups. This outcome varied 0 percent of the time, despite the fact that each patient received exactly the same placebo under identical conditions for the duration of the study. Dr. Illiot conceded that, in a study devoid of variables, there is no empirical value to segregating patients by group. She concluded, however, that an unintended benefit of the study was that it offered irrefutable proof that persons tapped for medical studies should, where possible, always opt to participate in Group "A."

"Our study, reviewing more than 700 consecutive Placebo Therapy case studies, further confirms the safety and efficacy of placebos for ALDD," said Dr. Illiot. "Patients evaluated in this study varied in age, common sense lapses and treatment histories. The vast majority of patients saw significant improvements in their decision-making ability. One notable exception, of course, was in connection with a common symptom of ALDD known as Line-Shifting Syndrome ("LSS"). Patients suffering ALDD usually exhibit symptoms of LSS at the supermarket or the EZ Pass/Fast Lane tollbooths. The results of LSS-induced decisions prove consistently to be disastrous. Medical science will probably never find a cure for LSS. Otherwise, Placebo Therapy continues to be an effective way to treat ALDD while possibly improving the quality-of-life for patients," said Dr. Illiot.

"Dr. Illiott's study reaffirms the safety, efficacy and quality-of-life benefits of  Placebo therapy for ALDD," said Gim E. Moore, president and CEO of Tasty Placebos, LLC (which contributed the placebos to the study). "Worldwide, more than 95,000,000 patients with ALDD have received our placebos, and a significant majority of these patients are consistently opting to continue treatment, which is evidenced by an initial reingestion rate of 98 percent, practically outpacing our ability to keep up with demand. These findings further establish Placebo Therapy as the best option for patients with ALDD who are not candidates for any other type of therapy or who have refused to cooperate with other therapies, such as those approved by insurance companies and the FDA."

Tasty Placebos, LLC provided 100% of the funding for the Placebo Therapy Study, peer reviewed it, and published the findings in major medical journals.

About Tasty Placebos, LLC and Placebo Therapy(®)

Tasty Placebos, LLC (Nasdaq: TPYUMYUM-x) is a medical placebo company with core expertise in M.D. neuromanipulation. The company developed and markets the Placebo Therapy System, which is kid-tested and mother-approved for the treatments of ALDD and treatment-resistant LSS. The Placebo Therapy System delivers a pleasant sensation to the anterior dorsum and into the oropharynx by way of the soft palate, upper esophagus and epiglottis.

Tasty Placebos, LLC markets the Placebo Therapy System in selected vending machines worldwide.